[Form 4] Emergent BioSolutions Inc. Insider Trading Activity

Rhea-AI Filing Summary

Emergent BioSolutions executive Coleen Glessner reported equity award outcomes and related share movements. On February 6, 2026, she recorded a disposition of 28,847 shares of common stock at $10.92 per share linked to performance stock units granted under the company’s stock incentive plan.

The Compensation Committee certified the 2023–2025 performance stock units at 25% of target, resulting in an actual award of 9,615 shares of common stock, compared with 38,462 shares previously reported for that grant. She also had 2,852 shares withheld at $10.92 per share to cover taxes on vesting and settlement of restricted stock units.

Following these transactions, Glessner directly beneficially owns 112,620 shares of Emergent BioSolutions common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Glessner Coleen

Role EVP, Quality & Ethics, and CPL

Type	Security	Shares	Price	Value
Disposition	Common Stock	28,847	$10.92	$315K
Tax Withholding	Common Stock	2,852	$10.92	$31K

Holdings After Transaction: Common Stock — 115,472 shares (Direct)

Footnotes (1)

1. Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 9,615 shares of common stock, which is less than the 38,462 shares previously reported on March 02, 2023 and June 09, 2023. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glessner Coleen

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Quality & Ethics, and CPL

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		D		28,847(1)	D	$10.92	115,472	D
Common Stock	02/06/2026		F		2,852(2)	D	$10.92	112,620	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 9,615 shares of common stock, which is less than the 38,462 shares previously reported on March 02, 2023 and June 09, 2023.

2. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the latest Form 4 for Emergent BioSolutions (EBS) report for Coleen Glessner?

The Form 4 shows Coleen Glessner recorded a disposition of 28,847 Emergent BioSolutions common shares and tax withholding of 2,852 shares. These movements are tied to performance stock units and restricted stock units under the company’s stock incentive programs.

How were Emergent BioSolutions’ 2023-2025 performance stock units certified for Coleen Glessner?

The Compensation Committee certified Glessner’s 2023-2025 performance stock units at 25% of target. That certification produced an actual award of 9,615 shares of common stock, compared with the 38,462 target shares previously reported for this performance-based equity grant.

Why were 2,852 Emergent BioSolutions (EBS) shares withheld in Coleen Glessner’s Form 4?

The 2,852 Emergent BioSolutions shares were withheld to pay taxes on vesting and settlement of restricted stock units. This withholding is reported with transaction code “F,” reflecting shares retained by the issuer instead of cash to satisfy tax obligations on the equity award.

How many Emergent BioSolutions shares does Coleen Glessner own after these transactions?

After the reported transactions, Coleen Glessner beneficially owns 112,620 shares of Emergent BioSolutions common stock directly. This figure reflects the net result of the performance stock unit certification, related share disposition, and the tax withholding tied to restricted stock unit vesting.

What role does Coleen Glessner hold at Emergent BioSolutions (EBS) as shown in the Form 4?

Coleen Glessner is listed as an officer of Emergent BioSolutions, serving as EVP, Quality & Ethics, and CPL. Her status as an executive officer requires ongoing reporting of equity transactions, including performance stock units and restricted stock units, on Form 4 under Section 16 rules.